GSK Buys Back Own Shares Via BNP Paribas
Ticker: GLAXF · Form: 6-K · Filed: Dec 3, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Dec 3, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction
TL;DR
GSK is buying back its own stock through BNP Paribas.
AI Summary
GSK plc announced on December 3, 2025, that it purchased a number of its own ordinary shares through its broker, BNP Paribas SA. The filing is a report of a foreign private issuer for the month of December 2025.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of share repurchases and does not indicate any new or significant risks.
Key Players & Entities
- GSK plc (company) — Registrant
- BNP Paribas SA (company) — Broker for share purchases
- 001-15170 (other) — SEC File Number
- 20251203 (date) — Filing date
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing reports on GSK plc's transaction in its own shares for the month of December 2025, acting through its broker BNP Paribas SA.
Who is acting as the broker for GSK's share purchases?
BNP Paribas SA is acting as the broker for GSK plc's purchase of its own ordinary shares.
What type of shares did GSK purchase?
GSK plc purchased its own ordinary shares of 31¼ pence each.
What is GSK plc's principal executive office address?
GSK plc's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Does GSK plc file annual reports under Form 20-F or Form 40-F?
GSK plc indicates that it files annual reports under cover of Form 20-F.
Filing Stats: 3,072 words · 12 min read · ~10 pages · Grade level 2.7 · Accepted 2025-12-03 08:52:06
Filing Documents
- a9639j.htm (6-K) — 2611KB
- 0001654954-25-013632.txt ( ) — 2613KB
From the Filing
IN OWN SHARES a9639j UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of December 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .     Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase: 02 December 2025 Aggregate number of ordinary shares of  31¼  pence each purchased: 200,000 Lowest price paid per share (GBp): 1,783.00p Highest price paid per share (GBp): 1,827.00p Volume-weighted average price paid per share (GBp): 1,815.48p   The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 30 September 2025. Since 30 September 2025, the Company has purchased 11,546,733 ordinary shares.   Following the above purchase, the Company will hold 237,011,577 ordinary shares in treasury and have 4,078,422,107 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,078,422,107. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 5.81 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.     Schedule of Purchases Shares purchased:   GSK plc (ISIN: GB00BN7SWP63) Date of purchases:   02 December 2025 Investment firm:      BNP Paribas SA     Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   20,666   1,827.00p   1,793.50p   1,818.76p   CHIX   62,198   1,827.00p   1,783.00p   1,815.45p   XLON   117,136   1,827.00p   1,783.00p   1,814.91p     Individual transactions:   Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   234   1786.5   XLON   02-Dec-2025   08:00:05   20251202156802421   150   1784.0   XLON   02-Dec-2025   08:00:25   20251202156803035   25   1783.0   CHIX   02-Dec-2025   08:00:27   20251202156803353   123   1783.0   XLON   02-Dec-2025   08:00:27   20251202156803355   238   1791.0